Clinical trial
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory…
NCT00310024 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00310024 |
|---|---|
| Title | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | bortezomib, vorinostat, laboratory biomarker analysis, pharmacological study |
| Enrollment | 40 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2008 |
| First posted | Apr 3, 2006 |
| Last update posted | Feb 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: